Zyclara (imiquimod) cream, 3.75%.
Department of Medicine, University of Toronto, Toronto, Canada.
Aditya K
AK
Gupta
Elizabeth A
EA
Cooper
William
W
Abramovits
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000279:Administration, Cutaneous; D000634:Aminoquinolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002170:Canada; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D000077271:Imiquimod; D055623:Keratosis, Actinic / Q000188:drug therapy* / Q000473:pathology; D014481:United States; D014486:United States Food and Drug Administration
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000077271:Imiquimod